Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Famelab, the Pop Idols of science communication
2017-03-09

Description: Famelab Tags: UFS, CUT, Science, Competition, research, British Council, Famelab, NRF

Oluwasegun Kuloyo and Zanele Matsane proved to be
Bloemfontein’s young and wittiest science researchers.
They will represent the Free State at the Famelab
national semifinals in Johannesburg.
Photo: Oteng Mpete

Imagine sharks with laser beams attached to their heads and enzymes that wear coats, and yeasts that stage a coup d’état in your body when agitated. This was all explored at the FameLab Science Communication Competition. 

Hosting the FameLab regional competition was a collaborative effort between Dr Mikateko Hoppener, from the University of the Free State’s (UFS), the Centre for Research on Higher Education and Development (CRHED), and Edith Sempe from the Central University of Technology (CUT), Research and Development Unit. Taking place for the first time in the Free State, the event was held at the UFS Centenary Complex on 2 March 2017.

Witty minds make science fun

FameLab is a competition that promotes science and technology by creating a space for scientists to find their voices and reach public audiences. The Free State regional competition had 18 contestants and two emerged victorious on the day. Contestants had to ensure their three-minute talks were fun, charismatic, clear and entertaining.

The two regional winners were Oluwasegun Kuloyo, a PhD student with the department of Microbial Biochemical and Food Biotechnology at UFS, and Zanele Matsane, a Construction Management PhD student at CUT. 

Kuloyo's research deals with the management of the candida yeast which exists in most people’s bodies and which, with a healthy immune system can be kept under control, but when an immune system is compromised, the yeast reacts volatilely and can potentially lead to death in HIV/AIDS patients. 

Matsane’s research is centred on collaborative construction management inspired by the Toyota manufacturing process. She hopes to resolve the silos of construction and bring about a more harmonious and fluid process to construction projects, thus ensuring their successful completion. 

The panel of judges consisted of Oteng Mpete UFS Media Liaison Officer, Dr Elizabeth Conradie from the CUT Innovation Hub, and Prof Willie du Preez from the CUT Centre for Rapid Prototyping and Manufacturing, as well as Robert Inglis from JiveMedia Africa.

Local scientists become jet-setters 
The two regional winners will head to Johannesburg to compete at the FameLab national semifinals, and the South African winner will go on to compete against winners from over 30 countries on an international stage, at the Cheltenham Science Festival in the UK.

FameLab is a programme of the Cheltenham Science Festival and is implemented locally by the South African Agency for Science and Technology Advancement (SAASTA), the British Council, and JiveMedia Africa. The competition has been running in South Africa for the past five years.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept